lansoprazole has been researched along with Asthma in 19 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
Excerpt | Relevance | Reference |
---|---|---|
"Asthma control as measured by the Asthma Control Questionnaire (ACQ) and other questionnaires from a 6-month clinical trial of lansoprazole in children with asthma was analyzed for associations with surrogates of lansoprazole exposure (based on treatment assignment and metabolizer phenotype)." | 9.20 | Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. ( Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wei, CY; Wise, RA, 2015) |
"To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER." | 9.16 | Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. ( Blake, K; Brown, ED; Castro, M; Dozor, AJ; Gold, BD; Holbrook, JT; Lima, JJ; Mastronarde, JG; Sockrider, MM; Teague, WG; Wise, RA, 2012) |
"Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo." | 9.11 | Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005) |
"The diagnosis of GERD was established by the method of Los Angeles classification including mucosal minimum change of Grade M and questionnaire for the diagnosis of reflux disease (QUEST) score." | 6.72 | A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. ( Dobashi, K; Ishizuka, T; Kawamura, O; Kobayashi, S; Kusano, M; Mori, M; Ohki, I; Shimizu, Y; Shimoyama, Y; Sunaga, N; Tokushima, M; Utsugi, M, 2006) |
"Asthma control as measured by the Asthma Control Questionnaire (ACQ) and other questionnaires from a 6-month clinical trial of lansoprazole in children with asthma was analyzed for associations with surrogates of lansoprazole exposure (based on treatment assignment and metabolizer phenotype)." | 5.20 | Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. ( Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wei, CY; Wise, RA, 2015) |
"Respiratory adverse events from a clinical trial of lansoprazole in children with asthma were analyzed for associations with extensive or poor metabolizer (PM) phenotype based on CYP2C19 haplotypes." | 5.17 | Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. ( Blake, KB; Gong, Y; Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wise, RA, 2013) |
"We analyzed 306 children between 6 and 17 years of age with poorly controlled asthma enrolled in a 6-month trial assessing lansoprazole for asthma control." | 5.17 | Obesity in children with poorly controlled asthma: Sex differences. ( Dixon, AE; Holbrook, JT; Irvin, CG; Lang, JE; Lima, JJ; Shade, D; Teague, WG; Wei, CY; Wise, RA, 2013) |
"To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER." | 5.16 | Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. ( Blake, K; Brown, ED; Castro, M; Dozor, AJ; Gold, BD; Holbrook, JT; Lima, JJ; Mastronarde, JG; Sockrider, MM; Teague, WG; Wise, RA, 2012) |
"Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo." | 5.11 | Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005) |
" The Genotype Tailored Treatment of Symptomatic Acid Reflux in Children with Uncontrolled Asthma (GenARA) study is a randomized, double-blind, placebo-controlled trial to determine if genotype-tailored PPI dosing improves asthma symptoms among children with inadequately controlled asthma and GERD symptoms." | 2.90 | Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods. ( Blake, KV; Cobbaert, M; Fischer, BM; Franciosi, J; Hossain, MJ; Lang, JE; Lima, JJ; Mougey, EB; Schmidt, S; Tang, M, 2019) |
"The diagnosis of GERD was established by the method of Los Angeles classification including mucosal minimum change of Grade M and questionnaire for the diagnosis of reflux disease (QUEST) score." | 2.72 | A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. ( Dobashi, K; Ishizuka, T; Kawamura, O; Kobayashi, S; Kusano, M; Mori, M; Ohki, I; Shimizu, Y; Shimoyama, Y; Sunaga, N; Tokushima, M; Utsugi, M, 2006) |
"Gastroesophageal reflux disease (GERD) influences the symptoms of asthma with acid and oxidative stress." | 1.34 | Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease. ( Dobashi, K; Hisada, T; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Ono, A; Shimizu, Y; Utsugi, M; Yanagitani, N; Zhao, JJ, 2007) |
"Gastroesophageal reflux disease (GERD) is commonly associated with asthma; however, frequency in nonatopic children with asthmatic symptoms is unknown." | 1.33 | Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease. ( Aydoğdu, S; Kasirga, E; Kirmaz, C; Yilmaz, O; Yüksel, H, 2006) |
"The causal association between gastro-oesophageal reflux disease (GERD) and difficult-to-control asthma is unclear." | 1.33 | Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy. ( Chua, CJ; Goh, KL; Liam, CK; Wong, CH, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 9 (47.37) | 29.6817 |
2010's | 9 (47.37) | 24.3611 |
2020's | 1 (5.26) | 2.80 |
Authors | Studies |
---|---|
Wang, WT | 1 |
Li, CY | 1 |
Chang, YT | 1 |
Bai, YM | 1 |
Tsai, SJ | 1 |
Chen, TJ | 1 |
Chiou, SH | 1 |
Chen, MH | 1 |
Tang, M | 1 |
Blake, KV | 1 |
Lima, JJ | 6 |
Mougey, EB | 3 |
Franciosi, J | 1 |
Schmidt, S | 1 |
Hossain, MJ | 1 |
Cobbaert, M | 1 |
Fischer, BM | 1 |
Lang, JE | 5 |
Blake, KB | 1 |
Gong, Y | 1 |
Holbrook, JT | 5 |
Wise, RA | 4 |
Teague, WG | 4 |
Pierog, AA | 1 |
Mencin, AA | 1 |
Wei, CY | 2 |
Sukhovershin, RA | 1 |
Ghebremariam, YT | 1 |
Cooke, JP | 1 |
Arand, M | 1 |
Gold, BD | 1 |
Blake, K | 1 |
Brown, ED | 1 |
Castro, M | 1 |
Dozor, AJ | 1 |
Mastronarde, JG | 1 |
Sockrider, MM | 1 |
Martinez, FD | 1 |
Dixon, AE | 1 |
Irvin, CG | 1 |
Shade, D | 1 |
Yüksel, H | 1 |
Yilmaz, O | 1 |
Kirmaz, C | 1 |
Aydoğdu, S | 1 |
Kasirga, E | 1 |
Littner, MR | 1 |
Leung, FW | 1 |
Ballard, ED | 1 |
Huang, B | 1 |
Samra, NK | 1 |
Katz, PO | 1 |
Wong, CH | 2 |
Chua, CJ | 1 |
Liam, CK | 1 |
Goh, KL | 2 |
Shimizu, Y | 2 |
Dobashi, K | 2 |
Kobayashi, S | 1 |
Ohki, I | 1 |
Tokushima, M | 1 |
Kusano, M | 1 |
Kawamura, O | 1 |
Shimoyama, Y | 1 |
Utsugi, M | 2 |
Sunaga, N | 1 |
Ishizuka, T | 2 |
Mori, M | 2 |
Sato, A | 1 |
Tanifuji, Y | 1 |
Kobayashi, H | 1 |
Inoue, H | 1 |
Zhao, JJ | 1 |
Kawata, T | 1 |
Ono, A | 1 |
Yanagitani, N | 1 |
Kaira, K | 1 |
Hisada, T | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase III: The Study of Acid Reflux in Children With Asthma[NCT00442013] | Phase 4 | 306 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Presence and degree of airway hyperresponsiveness; change from baseline to 24 weeks for airways reactivity assessed by methacholine post-diluent baseline (PC20) after medication holds (NCT00442013)
Timeframe: Measured at Weeks 0 and 24
Intervention | mg/mL (Mean) |
---|---|
Lansoprazole Group | 2.6 |
Placebo Group | 2.5 |
ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
Intervention | score (Mean) |
---|---|
Lansoprazole Group | 0.86 |
Placebo Group | 0.88 |
Scores range from 1 to 7 with higher values indicating better asthma-related quality of life; questionnaire measures functional impairments that are most troublesome to children as a result of their asthma; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
Intervention | score (Mean) |
---|---|
Lansoprazole Group | 5.8 |
Placebo Group | 6.0 |
Score ranges from 0 to 6, a lower score indicated better asthma control. Scores above 1.5 are indicative of poor asthma control; score obtained from questionnaire with 6 questions related to asthma control and FEV (amount of air expired in the first second during a forced expiratory maneuver); number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 24
Intervention | score (Mean) |
---|---|
Lansoprazole Group | 1.1 |
Placebo Group | 1.0 |
A measure of pulmonary function, specifically the amount of expired air in the first second during a forced expiratory maneuver while seated; test performed at least 4 hours after last dose of short-acting bronchodilator and at least 12 hours after long-acting bronchodilator; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
Intervention | Liters (Mean) |
---|---|
Lansoprazole Group | 2.2 |
Placebo Group | 2.3 |
"Episodes of poor asthma control are defined as any one of the following:~2 consecutive days with peak flow at less than 70% of baseline~prescription of oral corticosteroids for asthma~seeking urgent medical care for asthma symptoms~EPAC was measured by review of daily diaries that were maintained over the entire course of followup, i.e, 24 weeks" (NCT00442013)
Timeframe: Measured daily for 24 weeks by diary
Intervention | number of episodes of poor asthma contrl (Number) |
---|---|
Lansoprazole Group | 230 |
Placebo Group | 184 |
1 review available for lansoprazole and Asthma
Article | Year |
---|---|
Gastroesophageal reflux disease and extraesophageal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Benzimidazoles; Esophageal pH Mo | 2005 |
7 trials available for lansoprazole and Asthma
Article | Year |
---|---|
Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.
Topics: Adolescent; Asthma; Body Weights and Measures; Child; Cytochrome P-450 CYP2C19; Double-Blind Method; | 2019 |
Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Aryl Hydrocarbon Hydroxylases; Asthma; Bronchit | 2013 |
Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype.
Topics: Adolescent; Asthma; Child; Cytochrome P-450 CYP2C19; Drug Monitoring; Female; Gastroesophageal Reflu | 2015 |
Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adolescent; Adrenal Cortex Horm | 2012 |
Obesity in children with poorly controlled asthma: Sex differences.
Topics: Adolescent; Asthma; Body Mass Index; Child; Cohort Studies; Female; Forced Expiratory Volume; Humans | 2013 |
Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adrenal Cortex Hormones; Adult; | 2005 |
A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Asthma; Drug Evaluation; | 2006 |
11 other studies available for lansoprazole and Asthma
Article | Year |
---|---|
Proton-pump inhibitors are associated with an increased risk of asthma: A nationwide nested case-control study.
Topics: Asthma; Case-Control Studies; Esomeprazole; Female; Humans; Lansoprazole; Male; Proton Pump Inhibito | 2023 |
A childhood case of eosinophilic gastritis and protein-losing enteropathy.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Asthma; Child, Preschool; Cromol | 2014 |
Lansoprazole worsens asthma control in poor metabolizers: is nitric oxide involved?
Topics: Asthma; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Lansopra | 2015 |
Reply: worsening asthma control in children taking lansoprazole: possible mechanisms.
Topics: Asthma; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Lansopra | 2015 |
[Nocturnal shortness of breath: in asthma look for reflux -- is it worthwhile?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Asthma; Bronchodilator Agents; Gastroesophageal Reflux; Hum | 2008 |
Children, asthma, and proton pump inhibitors: costs and perils of therapeutic creep.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Asthma; Enzyme Inhibitors; Female; Humans; Lansoprazole; Ma | 2012 |
Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Asthmatic Agents; Anti-Ulcer Agents; Asthma; Child; Ch | 2006 |
Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Asthma; Cohort Studies; Female; Forced Expiratory | 2006 |
[Effects of proton pump inhibitor on airway hyperresponsiveness in asthmatics with gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Female; Gastroesophageal Reflux; | 2006 |
The role of proton-pump inhibitor therapy in patients with gastroesophageal reflux disease and difficult-to-control asthma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Gastroesophageal Reflux; Humans; | 2006 |
Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Asthma; Biomarkers; Breath Tests; Comorbidity; Dinoprost; F | 2007 |